

2025 STARS MEASU					
Measure	MEASURE DESCRIPTION	WT.	AGE	DATE RANGE	
BP	Members diagnosed with hypertension (HTN) whose blood	3.0	18 - 85	Jan 1, 2025to Dec 31, 2025 (yearly)	
00**	pressure (BP) was controlled (<140/90 mm Hg)	1.0	50.74		
CS**	Breast Cancer Screening (Mammography or Exclusion)	1.0	50-74	Oct 1, 2023 to Dec 31, 2025 (27 months)	
	iFOBT/gFOBT- Fecal occult blood test		l –	Jan 1, 2025 to Dec 31, 2025 (yearly)	
COL	Flexible sigmoidoscopy CT Colonography	1.0	45-75	Jan 1, 2021 to Dec 31, 2025 (5 years)	
	Colonoscopy			Jan 1, 2016 to Dec 31, 2025 (10 years)	
	FIT-DNA Test			Jan 1, 2023 to Dec 31, 2025 (3 years)	
WMC	The percentage of women who suffered a fracture and who had				
	either a bone mineral density (BMD) test OR prescription for a drug	0.5	67-85	Jul 1, 2024 to Jun 30, 2025 (yearly)	
	to treat osteoporosis in the 180 days (6 months) after the fracture.			, a de	
	Appropriate documentation of medication reconciliation				
TRC-MRP*	performed within 30 days of discharge is required in the record (31	0.5	≥18	Jan 1, 2025 to Dec 1, 2025 (yearly)	
		0.5	210	3a111, 2023 to Dec 1, 2023 (yearry)	
	Total days) Patients diagnosed with ASCVD who were dispensed high-intensity		Male:		
	or moderate-intensity statin medications and remained on these		21-75		
SPC	1	1.0		Jan 1, 2025 to Dec 31, 2025 (yearly)	
GSD	medications for at least 80% of the treatment period		Female:		
	Manufacture the Toronton Toronton College		40-75		
	Members with Type 1 or Type 2 diabetes whose most recent				
	glycemic status (measured by hemoglobin A1c [HbA1c] or glucose	3.0	18-75	Jan 1 2005 to Doo 31 2005 (voorly)	
4 <i>3D</i>	management indicator [GMI]) was either below 8.0% or above 9.0%	3.0	10-/2	Jan 1, 2025 to Dec 31, 2025 (yearly)	
	during the measurement year. (Good control is defined as <8%)				
	Percentage of plan members with diabetes who had an eye exam				
EED***	(retinal) to check for damage from diabetes during the	1.0	18-75	Jan 1, 2025 to Dec 31, 2025 (yearly)	
	measurement year or had a negative eye exam in prior year.	1.0	16-75	Jan 1, 2025 to Dec 31, 2025 (yearly)	
	The percentage of members 18–85 years of age with diabetes				
KED	(type 1 and type 2) who received a kidney health evaluation,				
	defined by an estimated glomerular filtration rate (eGFR) AND a	0.5	18-85	Jan 1, 2025 to Dec 31, 2025 (yearly)	
	urine albumin-creatinine ratio (uACR), during the measurement				
	year.				
	For members 18 years of age and older, the number of acute				
	inpatient and observation stays during the measurement year that				
PCR	were followed by an unplanned acute readmission for any	1.0	≥18	Jan 1, 2025 to Dec 31, 2025(yearly)	
	diagnosis within 30 days and the predicted probality of an acute				
	readmissions.				
	The percentage of emergency department (ED) visits for members				
FMC	18 years of age and older who have multiple high-risk chronic	0.0	≥18	Jan 1, 2025 to Dec 31, 2025 (yearly)	
FIVIC	condistions who had a follow-up service within 7 days of the ED	0.0	210	3an 1, 2023 to Dec 31, 2023 (yearry)	
	visit.				
	R ADULTS (COA) SNP MEMBERS 66 AND OLDER				
COA FSA	Functional Status Assessment during measurement year	0.5	SNP≥66	Jan 1, 2025 to Dec 31, 2025 (yearly)	
COA MED REV	Medication review w/ presence of a medication list in the	0.5	CND, CC	lon 1 0005 to Do 71 0005 ()	
	medical record (needs to include both to close gap)	0.5	SNP≥66	Jan 1, 2025 to Dec 31, 2025 (yearly)	
PART D MEASUR	ES: SUPD & MEDICATION ADHERENCE				
	nt when prescriptions are filled more than 80% of the time; start date begins with	n first fill dat	e once the second	fill is obtained.	
	Diabetic patients with two fills of diabetes prescription				
SUPD	claims need to be dispensed statin medication.	1.0	40-75	Jan 1, 2025 to Dec 31, 2025 (yearly)	
	·		 		
MED ADH DM	Taking oral diabetes medication(s) as directed. Plan				
	members who take insulin are not included in the measure	3.0	≥18	Jan 1, 2025 to Dec 31, 2025 (yearly)	
MED ADH HTN	Taking blood pressure ACE or ARB medication(s) as directed	3.0	≥18	Jan 1, 2025 to Dec 31, 2025 (yearly)	
		5.0			
MED ADH CHOL	Taking cholesterol statin medication(s) as directed	3.0	≥18	Jan 1, 2025 to Dec 31, 2025 (yearly)	

^(*) This measure is collected as an indicator in the Transitions of Care (TRC)

^(**) CMS adding younger age range 40-49 -BCS will be rated using OLD age range but these new members will appear in the denominator starting in the fall of 2025 (***) EED will move to admin only

⁽Part D Measures) No reporting required from providers. The health plan evaluates prescription claims data for these measures.



2025 HEDIS CODING GUIDE					
CARE FOR OLDER ADULTS					
\square 1157F Advanced Care Planning or similar legal document present in the medical record					
□ 1158F Advanced Care Planning discussion documented in the medical record					
□ 1159F* Medication list documented in medical record					
□ 1160F* Medication Review by prescribing practitioner or clinical pharmacist documented in the medical record					
□ 1170F Functional status assessed					
*Both codes 1159F and 1160F need to be submitted together and with same date of service.					
BLOOD PRESSURE LEVELS					
□ 3078F Most recent diastolic blood pressure less than 80mm Hg					
□ 3079F Most recent diastolic blood pressure 80-89mm Hg					
□ 3080F Most recent diastolic blood pressure greater than or equal to 90 mm Hg					
□ 3074F Most recent systolic blood pressure less than 130 mm Hg					
□ 3075F Most recent systolic blood pressure 130 – 139 mm Hg					
\square 3077FMost recent systolic blood pressure greater than or equal to 140 mm Hg					
LABORATORY RESULTS					
□ 3044F Most recent hemoglobin A1c (HbA1c) level less than 7.0%					
\square 3051F Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than or equal to 8.0%					
\square 3052F Most recent hemoglobin A1c (HbA1c) level greater than α	or equal to 8.0% and less than or equal to 9.0%				
□ 3046F Most recent hemoglobin A1c (HbA1c) level greater than 9.0%					
EYE EXAM					
□ 2022F Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of					
retinopathy (Positive result in current year)					
2023F Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of					
retinopathy (Negative result in current year)					
OTHER					
□ 90756 Influenza virus vaccine	□ 98966 Telephone visit/encounter				
□ 1111F Medication reconciliation post-Discharge	□ 98967 Telephone visit/encounter				
□ Z02.89 Encounter for other administrative examination	□ 98968 Telephone visit/encounter				